Neuroprotective effects of leptin in the context of obesity and metabolic disorders

Neurobiology of Disease

Volumn 72, Issue Part A, 2014, Pages 61-71

  Davis, Cecilia ^a   Mudd, Jeremy ^a   Hawkins, Meredith ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes; Leptin; Leptin resistance; Metabolic disorder; Neurodegeneration; Obesity

Indexed keywords

ADENOVIRUS VECTOR; AMYLIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; ISOPROTEIN; JANUS KINASE 2; LENTIVIRUS VECTOR; LEPTIN; LEPTIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; NEUROPROTECTIVE AGENT;

AGING; ALZHEIMER DISEASE; APOPTOSIS; BLOOD BRAIN BARRIER; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; LIPODYSTROPHY; METABOLIC DISORDER; MOLECULAR MECHANICS; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARKINSON DISEASE; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BRAIN; DISEASE MODEL; HYPOTHALAMUS; METABOLISM; MOUSE; NERVE CELL; RAT;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; HYPOTHALAMUS; LEPTIN; MICE; NEURONS; NEUROPROTECTIVE AGENTS; OBESITY; PARKINSON DISEASE; RATS;

EID: 84909646539     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.04.012     Document Type: Review

References (166)

1. Abbott R.A., Cox M., Markus H., Tomkins A. Diet, body size and micronutrient status in Parkinson's disease. Eur. J. Clin. Nutr. 1992, 46:879-884.
2. Abbott R.D., Ross G.W., White L.R., Nelson J.S., Masaki K.H., Tanner C.M., Curb J.D., Blanchette P.L., Popper J.S., Petrovitch H. Midlife adiposity and the future risk of Parkinson's disease. Neurology 2002, 59:1051-1057.
3. Abbott R.D., Ross G.W., White L.R., Sanderson W.T., Burchfiel C.M., Kashon M., Sharp D.S., Masaki K.H., Curb J.D., Petrovitch H. Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J. Neurol. 2003, 250(Suppl. 3):III30-III39.
4. Alves G., Forsaa E.B., Pedersen K.F., Dreetz Gjerstad M., Larsen J.P. Epidemiology of Parkinson's disease. J. Neurol. 2008, 255(Suppl. 5):18-32.
5. Arthur D.B., Georgi S., Akassoglou K., Insel P.A. Inhibition of apoptosis by P2Y2 receptor activation: novel pathways for neuronal survival. J. Neurosci. 2006, 26:3798-3804.
6. Banks W.A. Enhanced leptin transport across the blood-brain barrier by alpha 1-adrenergic agents. Brain Res. 2001, 899:209-217.
7. Banks W.A., Farrell C.L. Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E10-E15.
8. Banks A.S., Davis S.M., Bates S.H., Myers M.G. Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem. 2000, 275:14563-14572.
9. Banks W.A., Coon A.B., Robinson S.M., Moinuddin A., Shultz J.M., Nakaoke R., Morley J.E. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 2004, 53:1253-1260.
10. Banks W.A., Farr S.A., Morley J.E. The effects of high fat diets on the blood-brain barrier transport of leptin: failure or adaptation?. Physiol. Behav. 2006, 88:244-248.
11. Baquet Z.C., Bickford P.C., Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J. Neurosci. 2005, 25:6251-6259.
12. Berra E., Diaz-Meco M.T., Moscat J. The activation of p38 and apoptosis by the inhibition of Erk is antagonized by the phosphoinositide 3-kinase/Akt pathway. J. Biol. Chem. 1998, 273:10792-10797.
13. Beyer P.L., Palarino M.Y., Michalek D., Busenbark K., Koller W.C. Weight change and body composition in patients with Parkinson's disease. J. Am. Diet. Assoc. 1995, 95:979-983.
14. Bigalke B., Schreitmuller B., Sopova K., Paul A., Stransky E., Gawaz M., Stellos K., Laske C. Adipocytokines and CD34 progenitor cells in Alzheimer's disease. PLoS One 2011, 6:e20286.
15. Bjorbak C., Elmquist J.K., Michl P., Ahima R.S., van Bueren A., McCall A.L., Flier J.S. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology 1998, 139:3485-3491.
16. Boghossian S., Dube M.G., Torto R., Kalra P.S., Kalra S.P. Hypothalamic clamp on insulin release by leptin-transgene expression. Peptides 2006, 27:3245-3254.
17. Boghossian S., Ueno N., Dube M.G., Kalra P., Kalra S. Leptin gene transfer in the hypothalamus enhances longevity in adult monogenic mutant mice in the absence of circulating leptin. Neurobiol. Aging 2007, 28:1594-1604.
18. Bonda D.J., Stone J.G., Torres S.L., Siedlak S.L., Perry G., Kryscio R., Jicha G., Casadesus G., Smith M.A., Zhu X., Lee H.G. Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. J. Neurochem. 2014, 128(1):162-172.
19. Brown C.V., Rhee P., Neville A.L., Sangthong B., Salim A., Demetriades D. Obesity and traumatic brain injury. J. Trauma 2006, 61:572-576.
20. Burgener S., Buettner L., Buckwalter K., Beattie E., Bossen A., Fick D., Fitzsimmons S., Kolanowski A., Richeson N., Rose K., Schreiner A., Specht J., Testad I., Yu F., McKenzie S. Evidence supporting nutritional interventions for persons in early stage Alzheimer's disease (AD). J. Nutr. Health Aging 2008, 12:18-21.
21. Cai H., Cong W.N., Ji S., Rothman S., Maudsley S., Martin B. Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr. Alzheimer Res. 2012, 9:5-17.
22. Carro E.M. Therapeutic approaches of leptin in Alzheimer's disease. Recent Pat. CNS Drug Discov. 2009, 4:200-208.
23. Chan J.L., Lutz K., Cochran E., Huang W., Peters Y., Weyer C., Gorden P. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr. Pract. 2011, 17:922-932.
24. Chen H., Charlat O., Tartaglia L.A., Woolf E.A., Weng X., Ellis S.J., Lakey N.D., Culpepper J., Moore K.J., Breitbart R.E., Duyk G.M., Tepper R.I., Morgenstern J.P. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996, 84:491-495.
25. Chen H., Zhang S.M., Hernan M.A., Willett W.C., Ascherio A. Weight loss in Parkinson's disease. Ann. Neurol. 2003, 53:676-679.
26. WAF1/CIP1>. Breast Cancer Res. Treat. 2006, 98:121-132.
27. Chen K., Li F., Li J., Cai H., Strom S., Bisello A., Kelley D.E., Friedman-Einat M., Skibinski G.A., McCrory M.A., Szalai A.J., Zhao A.Z. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat. Med. 2006, 12:425-432.
28. Choi J.-Y., Jang E.-H., Park C.-S., Kang J.-H. Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radic. Biol. Med. 2005, 38:806-816.
29. Clegg D.J., Gotoh K., Kemp C., Wortman M.D., Benoit S.C., Brown L.M., D'Alessio D., Tso P., Seeley R.J., Woods S.C. Consumption of a high-fat diet induces central insulin resistance independent of adiposity. Physiol. Behav. 2011, 103:10-16.
30. Correia M.L., Haynes W.G., Rahmouni K., Morgan D.A., Sivitz W.I., Mark A.L. The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002, 51:439-442.
31. Dicou E.C.A., Attoub S., Gressens P. Neuroprotective effects of leptin in vivo and in vitro. Neuroreport 2001, 12:3947-3951.
32. Dixon J.B. The effect of obesity on health outcomes. Mol. Cell. Endocrinol. 2010, 316:104-108.
33. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., Shen J., Vinson C., Rueger J.M., Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100:197-207.
34. Ebihara K., Kusakabe T., Hirata M., Masuzaki H., Miyanaga F., Kobayashi N., Tanaka T., Chusho H., Miyazawa T., Hayashi T., Hosoda K., Ogawa Y., DePaoli A.M., Fukushima M., Nakao K. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J. Clin. Endocrinol. Metab. 2007, 92:532-541.
35. Elias M.F., Elias P.K., Sullivan L.M., Wolf P.A., D'Agostino R.B. Lower cognitive function in the presence of obesity and hypertension: the Framingham Heart Study. Int. J. Obes. Relat. Metab. Disord. 2003, 27:260-268.
36. Elias M.F., Elias P.K., Sullivan L.M., Wolf P.A., D'Agostino R.B. Obesity, diabetes and cognitive deficit: the Framingham Heart Study. Neurobiol. Aging 2005, 26(Suppl. 1):11-16.
37. Elmquist J.K., Bjørbæk C., Ahima R.S., Flier J.S., Saper C.B. Distributions of leptin receptor mRNA isoforms in the rat brain. J. Comp. Neurol. 1998, 395:535-547.
38. Enriori P.J., Evans A.E., Sinnayah P., Cowley M.A. Leptin resistance and obesity. Obesity (Silver Spring) 2006, 14(Suppl. 5):254S-258S.
39. Enriori P.J., Sinnayah P., Simonds S.E., Garcia Rudaz C., Cowley M.A. Leptin action in the dorsomedial hypothalamus increases sympathetic tone to brown adipose tissue in spite of systemic leptin resistance. J. Neurosci. 2011, 31:12189-12197.
40. Evidente V.G., Caviness J.N., Adler C.H., Gwinn-Hardy K.A., Pratley R.E. Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. Mov. Disord. 2001, 16:924-927.
41. Farooqi I.S., Jebb S.A., Langmack G., Lawrence E., Cheetham C.H., Prentice A.M., Hughes I.A., McCamish M.A., O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 1999, 341:879-884.
42. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4162-4167.
43. Fernandez-Galaz C., Fernandez-Agullo T., Campoy F., Arribas C., Gallardo N., Andres A., Ros M., Carrascosa J.M. Decreased leptin uptake in hypothalamic nuclei with ageing in Wistar rats. J. Endocrinol. 2001, 171:23-32.
44. Fewlass D.C., Noboa K., Pi-Sunyer F.X., Johnston J.M., Yan S.D., Tezapsidis N. Obesity-related leptin regulates Alzheimer's Abeta. FASEB J. 2004, 18:1870-1878.
45. Figlewicz D.P., Naleid A.M., Sipols A.J. Modulation of food reward by adiposity signals. Physiol. Behav. 2007, 91:473-478.
46. Fitzpatrick A.L., Kuller L.H., Lopez O.L., Diehr P., O'Meara E.S., Longstreth W.T., Luchsinger J.A. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch. Neurol. 2009, 66:336-342.
47. Frühbeck G. Intracellular signalling pathways activated by leptin. Biochem. J. 2006, 393:7-20.
48. Gorospe E.C., Dave J.K. The risk of dementia with increased body mass index. Age Ageing 2007, 36:23-29.
49. Greco S.J., Sarkar S., Johnston J.M., Tezapsidis N. Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem. Biophys. Res. Commun. 2009, 380:98-104.
50. Greco S.J., Bryan K.J., Sarkar S., Zhu X., Smith M.A., Ashford J.W., Johnston J.M., Tezapsidis N., Casadesus G. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:1155-1167.
51. Greenberg A.S., Shen W.J., Muliro K., Patel S., Souza S.C., Roth R.A., Kraemer F.B. Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway. J. Biol. Chem. 2001, 276:45456-45461.
52. Guo Z., Jiang H., Xu X., Duan W., Mattson M.P. Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization. J. Biol. Chem. 2008, 283:1754-1763.
53. Gustafson D.R., Backman K., Waern M., Ostling S., Guo X., Zandi P., Mielke M.M., Bengtsson C., Skoog I. Adiposity indicators and dementia over 32years in Sweden. Neurology 2009, 73:1559-1566.
54. Harada A., Oguchi K., Okabe S., Kuno J., Terada S., Ohshima T., Sato-Yoshitake R., Takei Y., Noda T., Hirokawa N. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 1994, 369:488-491.
55. Harvey J. Leptin regulation of neuronal excitability and cognitive function. Curr. Opin. Pharmacol. 2007, 7:643-647.
56. Hassing L.B., Dahl A.K., Thorvaldsson V., Berg S., Gatz M., Pedersen N.L., Johansson B. Overweight in midlife and risk of dementia: a 40-year follow-up study. Int. J. Obes. (Lond.) 2009, 33:893-898.
57. Hebert L.E., Weuve J., Scherr P.A., Evans D.A. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013, 80:1778-1783.
58. Hileman S.M., Pierroz D.D., Masuzaki H., Bjorbaek C., El-Haschimi K., Banks W.A., Flier J.S. Characterizaton of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology 2002, 143:775-783.
59. Ho P.W., Liu H.F., Ho J.W., Zhang W.Y., Chu A.C., Kwok K.H., Ge X., Chan K.H., Ramsden D.B., Ho S.L. Mitochondrial uncoupling protein-2 (UCP2) mediates leptin protection against MPP+toxicity in neuronal cells. Neurotox. Res. 2010, 17:332-343.
60. Holden K.F., Lindquist K., Tylavsky F.A., Rosano C., Harris T.B., Yaffe K. Serum leptin level and cognition in the elderly: findings from the Health ABC Study. Neurobiol. Aging 2009, 30:1483-1489.
61. Hospital UoSPG Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition 2011, (Sao Paolo (Brazil)).
62. Ittner L.M., Gotz J. Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:65-72.
63. Jacobs B., Beems T., Stulemeijer M., van Vugt A.B., van der Vliet T.M., Borm G.F., Vos P.E. Outcome prediction in mild traumatic brain injury: age and clinical variables are stronger predictors than CT abnormalities. J. Neurotrauma 2010, 27:655-668.
64. Janson J., Laedtke T., Parisi J.E., O'Brien P., Petersen R.C., Butler P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481.
65. Johnston J.M., Greco S.J., Hamzelou A., Ashford J.W., Tezapsidis N. Repositioning leptin as a therapy for Alzheimer's disease. Therapy 2011, 8:481-490.
66. Kaiyala K.J., Morton G.J., Leroux B.G., Ogimoto K., Wisse B., Schwartz M.W. Identification of body fat mass as a major determinant of metabolic rate in mice. Diabetes 2010, 59:1657-1666.
67. Kalra S.P. Central leptin insufficiency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions. Peptides 2008, 29:127-138.
68. Kalra S.P., Kalra P.S. Neuroendocrine control of energy homeostasis: update on new insights. Prog. Brain Res. 2010, 181:17-33.
69. Kalra S.P., Dube M.G., Pu S., Xu B., Horvath T.L., Kalra P.S. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. 1999, 20:68-100.
70. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., Bland R.J., Young D., Strybing K., Eidelberg D., During M.J. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007, 369:2097-2105.
71. Kastin A.J., Pan W., Maness L.M., Koletsky R.J., Ernsberger P. Decreased transport of leptin across the blood-brain barrier in rats lacking the short form of the leptin receptor. Peptides 1999, 20:1449-1453.
72. Katz D.I., Alexander M.P. Traumatic brain injury. Predicting course of recovery and outcome for patients admitted to rehabilitation. Arch. Neurol. 1994, 51:661-670.
73. Kim B., Backus C., Oh S., Hayes J.M., Feldman E.L. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 2009, 150:5294-5301.
74. Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kareholt I., Winblad B., Helkala E.L., Tuomilehto J., Soininen H., Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 2005, 62:1556-1560.
75. Klein S., Coppack S.W., Mohamed-Ali V., Landt M. Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 1996, 45:984-987.
76. Kohno R., Sawada H., Kawamoto Y., Uemura K., Shibasaki H., Shimohama S. BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line. Biochem. Biophys. Res. Commun. 2004, 318:113-118.
77. Konner A.C., Klockener T., Bruning J.C. Control of energy homeostasis by insulin and leptin: targeting the arcuate nucleus and beyond. Physiol. Behav. 2009, 97:632-638.
78. Kowal S.L., Dall T.M., Chakrabarti R., Storm M.V., Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord. 2013, 28:311-318.
79. Kreier F., Kap Y.S., Mettenleiter T.C., van Heijningen C., van der Vliet J., Kalsbeek A., Sauerwein H.P., Fliers E., Romijn J.A., Buijs R.M. Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. Endocrinology 2006, 147:1140-1147.
80. Lee E.B. Obesity, leptin, and Alzheimer's disease. Ann. N. Y. Acad. Sci. 2011, 1243:15-29.
81. Lee G.H., Proenca R., Montez J.M., Carroll K.M., Darvishzadeh J.G., Lee J.I., Friedman J.M. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996, 379:632-635.
82. Lee C.J., Liao C.L., Lin Y.L. Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection. J. Virol. 2005, 79:8388-8399.
83. Leshan R.L., Bjornholm M., Munzberg H., Myers M.G. Leptin receptor signaling and action in the central nervous system. Obesity 2006, 14:208S-212S.
84. Li H., Matheny M., Nicolson M., Tumer N., Scarpace P.J. Leptin gene expression increases with age independent of increasing adiposity in rats. Diabetes 1997, 46:2035-2039.
85. Li Q., Zhang R., Guo Y.L., Mei Y.W. Effect of neuregulin on apoptosis and expressions of STAT3 and GFAP in rats following cerebral ischemic reperfusion. J. Mol. Neurosci. 2009, 37:67-73.
86. Lieb W., Beiser A.S., Vasan R.S., Tan Z.S., Au R., Harris T.B., Roubenoff R., Auerbach S., DeCarli C., Wolf P.A., Seshadri S. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 2009, 302:2565-2572.
87. Lonze B.E., Ginty D.D. Function and regulation of CREB family transcription factors in the nervous system. Neuron 2002, 35:605-623.
88. Louis G., Myers M. The role of leptin in the regulation of neuroendocrine function and CNS development. Rev. Endocr. Metab. Disord. 2007, 8:85-94.
89. Lu J., Park C.-S., Lee S.-K., Shin D.W., Kang J.-H. Leptin inhibits 1-methyl-4-phenylpyridinium-induced cell death in SH-SY5Y cells. Neurosci. Lett. 2006, 407:240-243.
90. Lund I.K., Hansen J.A., Andersen H.S., Moller N.P., Billestrup N. Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling. J. Mol. Endocrinol. 2005, 34:339-351.
91. Mark A.L. Selective leptin resistance revisited. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 305:R566-R581.
92. Mark A.L., Correia M.L., Rahmouni K., Haynes W.G. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J. Hypertens. 2002, 20:1245-1250.
93. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., Taylor R., Cahn-Weiner D.A., Stoessl A.J., Olanow C.W., Bartus R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008, 7:400-408.
94. Marks W.J., Bartus R.T., Siffert J., Davis C.S., Lozano A., Boulis N., Vitek J., Stacy M., Turner D., Verhagen L., Bakay R., Watts R., Guthrie B., Jankovic J., Simpson R., Tagliati M., Alterman R., Stern M., Baltuch G., Starr P.A., Larson P.S., Ostrem J.L., Nutt J., Kieburtz K., Kordower J.H., Olanow C.W. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010, 9:1164-1172.
95. Matochik J.A., London E.D., Yildiz B.O., Ozata M., Caglayan S., DePaoli A.M., Wong M.L., Licinio J. Effect of leptin replacement on brain structure in genetically leptin-deficient adults. J. Clin. Endocrinol. Metab. 2005, 90:2851-2854.
96. Mayeux R., Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb. Perspect Med. 2012, 2.
97. McKnight S.L. WAT-free mice: diabetes without obesity. Genes Dev. 1998, 12:3145-3148.
98. Misiak B., Leszek J., Kiejna A. Metabolic syndrome, mild cognitive impairment and Alzheimer's disease-the emerging role of systemic low-grade inflammation and adiposity. Brain Res. Bull. 2012, 89:144-149.
99. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 1999, 270:45-48.
100. Morash B., Li A., Murphy P.R., Wilkinson M., Ur E. Leptin gene expression in the brain and pituitary gland. Endocrinology 1999, 140:5995-5998.
101. Morris J.K., Bomhoff G.L., Stanford J.A., Geiger P.C. Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 299:R1082-R1090.
102. Morrison C.D., White C.L., Wang Z., Lee S.Y., Lawrence D.S., Cefalu W.T., Zhang Z.Y., Gettys T.W. Increased hypothalamic protein tyrosine phosphatase 1B contributes to leptin resistance with age. Endocrinology 2007, 148:433-440.
103. Moschos S., Chan J.L., Mantzoros C.S. Leptin and reproduction: a review. Fertil. Steril. 2002, 77:433-444.
104. Mosenthal A.C., Livingston D.H., Lavery R.F., Knudson M.M., Lee S., Morabito D., Manley G.T., Nathens A., Jurkovich G., Hoyt D.B., Coimbra R. The effect of age on functional outcome in mild traumatic brain injury: 6-month report of a prospective multicenter trial. J. Trauma 2004, 56:1042-1048.
105. Munzberg H., Myers M.G. Molecular and anatomical determinants of central leptin resistance. Nat. Neurosci. 2005, 8:566-570.
106. Murase S., Kim E., Lin L., Hoffman D.A., McKay R.D. Loss of signal transducer and activator of transcription 3 (STAT3) signaling during elevated activity causes vulnerability in hippocampal neurons. J. Neurosci. 2012, 32:15511-15520.
107. Myers M.G., Cowley M.A., Münzberg H. Mechanisms of leptin action and leptin resistance. Annu. Rev. Physiol. 2008, 70:537-556.
108. Myers M.G., Leibel R.L., Seeley R.J., Schwartz M.W. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol. Metab. 2010, 21:643-651.
109. Najib S., Sánchez-Margalet V. Human leptin promotes survival of human circulating blood monocytes prone to apoptosis by activation of p42/44 MAPK pathway. Cell. Immunol. 2002, 220:143-149.
110. Neville A.L., Brown C.V., Weng J., Demetriades D., Velmahos G.C. Obesity is an independent risk factor of mortality in severely injured blunt trauma patients. Arch. Surg. 2004, 139:983-987.
111. Oomura Y., Hori N., Shiraishi T., Fukunaga K., Takeda H., Tsuji M., Matsumiya T., Ishibashi M., Aou S., Li X.L., Kohno D., Uramura K., Sougawa H., Yada T., Wayner M.J., Sasaki K. Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides 2006, 27:2738-2749.
112. Oral E.A., Simha V., Ruiz E., Andewelt A., Premkumar A., Snell P., Wagner A.J., DePaoli A.M., Reitman M.L., Taylor S.I., Gorden P., Garg A. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 2002, 346:570-578.
113. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53:1937-1942.
114. Pannacciulli N., Del Parigi A., Chen K., Le D.S., Reiman E.M., Tataranni P.A. Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage 2006, 31:1419-1425.
115. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., Raisman-Vozari R. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 1999, 10:557-561.
116. Patel N.V., Gordon M.N., Connor K.E., Good R.A., Engelman R.W., Mason J., Morgan D.G., Morgan T.E., Finch C.E. Caloric restriction attenuates A[beta]-deposition in Alzheimer transgenic models. Neurobiol. Aging 2005, 26:995-1000.
117. Paz-Filho G., Wong M.L., Licinio J. The procognitive effects of leptin in the brain and their clinical implications. Int. J. Clin. Pract. 2010, 64:1808-1812.
118. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002, 51:1256-1262.
119. Peralta S., Carrascosa J.M., Gallardo N., Ros M., Arribas C. Ageing increases SOCS-3 expression in rat hypothalamus: effects of food restriction. Biochem. Biophys. Res. Commun. 2002, 296:425-428.
120. Perez-Gonzalez R., Alvira-Botero M.X., Robayo O., Antequera D., Garzon M., Martin-Moreno A.M., Brera B., de Ceballos M.L., Carro E. Leptin gene therapy attenuates neuronal damages evoked by amyloid-beta and rescues memory deficits in APP/PS1 mice. Gene Ther. 2014, 21:298-308.
121. Petersen K.F., Oral E.A., Dufour S., Befroy D., Ariyan C., Yu C., Cline G.W., DePaoli A.M., Taylor S.I., Gorden P., Shulman G.I. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 2002, 109:1345-1350.
122. Pharmaceuticals B-MSA An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy 2008, National Library of Medicine (US), Bethesda (MD).
123. Pharmaceuticals B-MSA Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects 2008, National Library of Medicine (US), Bethesda (MD).
124. Power D.A., Noel J., Collins R., O'Neill D. Circulating leptin levels and weight loss in Alzheimer's disease patients. Dement. Geriatr. Cogn. Disord. 2001, 12:167-170.
125. Rahmouni K., Morgan D.A. Hypothalamic arcuate nucleus mediates the sympathetic and arterial pressure responses to leptin. Hypertension 2007, 49:647-652.
126. Rahmouni K., Haynes W.G., Morgan D.A., Mark A.L. Selective resistance to central neural administration of leptin in agouti obese mice. Hypertension 2002, 39:486-490.
127. Rahmouni K., Morgan D.A., Morgan G.M., Mark A.L., Haynes W.G. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005, 54:2012-2018.
128. Roth J.D., Roland B.L., Cole R.L., Trevaskis J.L., Weyer C., Koda J.E., Anderson C.M., Parkes D.G., Baron A.D. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7257-7262.
129. Rotter V., Nagaev I., Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 2003, 278:45777-45784.
130. Rountree S.D., Chan W., Pavlik V.N., Darby E.J., Siddiqui S., Doody R.S. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res. Ther. 2009, 1:7.
131. RS S. Obesity in the elderly. Handbook of Obesity 1998, 103-114. Marcel Dekker, New York. G.A. Bray, BC, W.P.T. James (Eds.).
132. Russo V.C., Metaxas S., Kobayashi K., Harris M., Werther G.A. Antiapoptotic effects of leptin in human neuroblastoma cells. Endocrinology 2004, 145:4103-4112.
133. Savage D.B., O'Rahilly S. Leptin: a novel therapeutic role in lipodystrophy. J. Clin. Invest. 2002, 109:1285-1286.
134. Saxena N.K., Titus M.A., Ding X., Floyd J., Srinivasan S., Sitaraman S.V., Anania F.A. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J. 2004, 18(13):1612-1614.
135. Scarpace P.J., Matheny M., Moore R.L., Tumer N. Impaired leptin responsiveness in aged rats. Diabetes 2000, 49:431-435.
136. Shanley L.J., Irving A.J., Harvey J. Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J. Neurosci. 2001, 21:186RC.
137. Shimabukuro M., Wang M.-Y., Zhou Y.-T., Newgard C.B., Unger R.H. Protection against lipoapoptosis of β cells through leptin-dependent maintenance of Bcl-2 expression. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9558-9561.
138. Signore A.P., Zhang F., Weng Z., Gao Y., Chen J. Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials. J. Neurochem. 2008, 106:1977-1990.
139. Simons L.A., Simons J., McCallum J., Friedlander Y. Lifestyle factors and risk of dementia: Dubbo Study of the elderly. Med. J. Aust. 2006, 184:68-70.
140. Spina M.B., Squinto S.P., Miller J., Lindsay R.M., Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 1992, 59:99-106.
141. Sriram K., Benkovic S.A., Miller D.B., O'Callaghan J.P. Obesity exacerbates chemically induced neurodegeneration. Neuroscience 2002, 115:1335-1346.
142. Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T., Yasuda M., Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y., Tanaka C. Phosphorylation of tau is regulated by PKN. J. Biol. Chem. 2001, 276:10025-10031.
143. Terao S., Yilmaz G., Stokes K.Y., Ishikawa M., Kawase T., Granger D.N. Inflammatory and injury responses to ischemic stroke in obese mice. Stroke 2008, 39:943-950.
144. Udagawa J., Otani H. 6D-1 the role of leptin in fetal brain development. Early Hum. Dev. 2007, 83:45.
145. Ueno N., Inui A., Kalra P.S., Kalra S.P. Leptin transgene expression in the hypothalamus enforces euglycemia in diabetic, insulin-deficient nonobese Akita mice and leptin-deficient obese ob/ob mice. Peptides 2006, 27:2332-2342.
146. Uyama N., Geerts A., Reynaert H. Neural connections between the hypothalamus and the liver. Anat. Rec. A: Discov. Mol. Cell. Evol. Biol. 2004, 280:808-820.
147. Wang X.-P., Ding H.-L. Alzheimer's disease: epidemiology, genetics, and beyond. Neurosci. Bull. 2008, 24:105-109.
148. Wang G.J., Volkow N.D., Logan J., Pappas N.R., Wong C.T., Zhu W., Netusil N., Fowler J.S. Brain dopamine and obesity. Lancet 2001, 357:354-357.
149. Wang R., Li J.J., Diao S., Kwak Y.D., Liu L., Zhi L., Bueler H., Bhat N.R., Williams R.W., Park E.A., Liao F.F. Metabolic stress modulates Alzheimer's beta-secretase gene transcription via SIRT1-PPARgamma-PGC-1 in neurons. Cell Metab. 2013, 17:685-694.
150. Wang L., Zhai Y.Q., Xu L.L., Qiao C., Sun X.L., Ding J.H., Lu M., Hu G. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp. Neurol. 2014, 251:22-29.
151. Ward M.A., Carlsson C.M., Trivedi M.A., Sager M.A., Johnson S.C. The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study. BMC Neurol. 2005, 5:23.
152. Weng Z., Signore A.P., Gao Y., Wang S., Zhang F., Hastings T., Yin X.M., Chen J. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. J. Biol. Chem. 2007, 282:34479-34491.
153. Whitmer R.A., Gunderson E.P., Barrett-Connor E., Quesenberry C.P., Yaffe K. Obesity in middle age and future risk of dementia: a 27year longitudinal population based study. BMJ 2005, 330:1360.
154. Whitmer R.A., Gunderson E.P., Quesenberry C.P., Zhou J., Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr. Alzheimer Res. 2007, 4:103-109.
155. Whitmer R.A., Gustafson D.R., Barrett-Connor E., Haan M.N., Gunderson E.P., Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 2008, 71:1057-1064.
156. WHO Obesity and Overweight: Fact Sheet No 311 2013, WHO.
157. Wiesner G., Vaz M., Collier G., Seals D., Kaye D., Jennings G., Lambert G., Wilkinson D., Esler M. Leptin is released from the human brain: influence of adiposity and gender. J. Clin. Endocrinol. Metab. 1999, 84:2270-2274.
158. Wolf P.A., Beiser A., Elias M.F., Au R., Vasan R.S., Seshadri S. Relation of obesity to cognitive function: importance of central obesity and synergistic influence of concomitant hypertension. The Framingham Heart Study. Curr. Alzheimer Res. 2007, 4:111-116.
159. Wu-Peng X.S., Chua S.C., Okada N., Liu S.M., Nicolson M., Leibel R.L. Phenotype of the obese Koletsky (f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor (Lepr): evidence for deficient plasma-to-CSF transport of leptin in both the Zucker and Koletsky obese rat. Diabetes 1997, 46:513-518.
160. Wurtman R.J. What is leptin for, and does it act on the brain?. Nat. Med. 1996, 2:492-493.
161. Xu W.L., Atti A.R., Gatz M., Pedersen N.L., Johansson B., Fratiglioni L. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 2011, 76:1568-1574.
162. Zeki Al Hazzouri A., Haan M.N., Whitmer R.A., Yaffe K., Neuhaus J. Central obesity, leptin and cognitive decline: the Sacramento Area Latino Study on Aging. Dement. Geriatr. Cogn. Disord. 2012, 33:400-409.
163. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
164. Zhang F., Wang S., Signore A.P., Chen J. Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia. Stroke 2007, 38:2329-2336.
165. Zhang J.Y., Yan G.T., Liao J., Deng Z.H., Xue H., Wang L.H., Zhang K. Leptin attenuates cerebral ischemia/reperfusion injury partially by CGRP expression. Eur. J. Pharmacol. 2011, 671:61-69.
166. Zhang J., Deng Z., Liao J., Song C., Liang C., Xue H., Wang L., Zhang K., Yan G. Leptin attenuates cerebral ischemia injury through the promotion of energy metabolism via the PI3K/Akt pathway. J. Cereb. Blood Flow Metab. 2013, 33:567-574.